Ji Luo, Ph.D. - Publications

Affiliations: 
Harvard University, Cambridge, MA, United States 
Area:
PI3K and cancer metabolism

50 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Zhang H, Luo J. SUMO wrestling with Ras. Small Gtpases. 0. PMID 27057691 DOI: 10.1080/21541248.2016.1161698  0.68
2016 Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, Gutkind JS. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. PMID 26882569 DOI: 10.18632/oncotarget.7372  0.68
2015 Wang Y, Yang H, Shen C, Luo J. Cholangiocarcinoma: prognostic factors after surgical resection in China. International Journal of Clinical and Experimental Medicine. 8: 5506-12. PMID 26131130  0.68
2015 Jossé R, Zhang YW, Giroux V, Ghosh AK, Luo J, Pommier Y. Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. Marine Drugs. 13: 3625-39. PMID 26058013 DOI: 10.3390/md13063625  0.68
2015 Yu B, Swatkoski S, Holly A, Lee LC, Giroux V, Lee CS, Hsu D, Smith JL, Yuen G, Yue J, Ann DK, Simpson RM, Creighton CJ, Figg WD, Gucek M, ... Luo J, et al. Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proceedings of the National Academy of Sciences of the United States of America. 112: E1724-33. PMID 25805818 DOI: 10.1073/pnas.1415569112  0.68
2014 Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nature Reviews. Drug Discovery. 13: 828-51. PMID 25323927 DOI: 10.1038/nrd4389  0.68
2014 Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, Ried T, Luo J, Caplen NJ, Lal A. Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. Oncotarget. 5: 7635-50. PMID 25245095  0.68
2014 Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discovery. 4: 1182-97. PMID 25100204 DOI: 10.1158/2159-8290.CD-13-0900  0.68
2014 Carver J, Dexheimer TS, Hsu D, Weng MT, Smith JL, Guha R, Jadhav A, Simeonov A, Luo J. A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. Plos One. 9: e103836. PMID 25093678 DOI: 10.1371/journal.pone.0103836  0.68
2014 Lee LC, Gao S, Li Q, Luo J. Using pooled miR30-shRNA library for cancer lethal and synthetic lethal screens. Methods in Molecular Biology (Clifton, N.J.). 1176: 45-58. PMID 25030918 DOI: 10.1007/978-1-4939-0992-6_5  0.68
2014 Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, et al. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. The Journal of Clinical Investigation. 124: 3003-15. PMID 24911146 DOI: 10.1172/JCI73048  0.68
2014 Luo J, Korossis SA, Wilshaw SP, Jennings LM, Fisher J, Ingham E. Development and characterization of acellular porcine pulmonary valve scaffolds for tissue engineering. Tissue Engineering. Part A. 20: 2963-74. PMID 24786313 DOI: 10.1089/ten.TEA.2013.0573  0.68
2014 Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yang Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, et al. A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Molecular and Cellular Biology. 34: 533-50. PMID 24277930 DOI: 10.1128/MCB.01043-13  0.68
2013 Yu B, Luo J. Synthetic lethal genetic screens in Ras mutant cancers. The Enzymes. 34: 201-19. PMID 25034106 DOI: 10.1016/B978-0-12-420146-0.00009-3  0.68
2013 Weng MT, Luo J. The enigmatic ERH protein: its role in cell cycle, RNA splicing and cancer. Protein & Cell. 4: 807-12. PMID 24078386 DOI: 10.1007/s13238-013-3056-3  0.68
2012 Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, ... ... Luo J, et al. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 109: E3659-67. PMID 23236152 DOI: 10.1073/pnas.1207673110  0.68
2012 Solimini NL, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, Burrows AE, Anselmo AN, Bredemeyer AL, Li MZ, Beroukhim R, Meyerson M, Elledge SJ. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (New York, N.Y.). 337: 104-9. PMID 22628553 DOI: 10.1126/science.1219580  0.68
2012 Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu ZG. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proceedings of the National Academy of Sciences of the United States of America. 109: 5322-7. PMID 22421439 DOI: 10.1073/pnas.1200012109  0.68
2012 Hu G, Luo J. A primer on using pooled shRNA libraries for functional genomic screens. Acta Biochimica Et Biophysica Sinica. 44: 103-12. PMID 22271906 DOI: 10.1093/abbs/gmr116  0.68
2012 Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, ... ... Luo J, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (New York, N.Y.). 335: 348-53. PMID 22157079 DOI: 10.1126/science.1212728  0.68
2011 Luo J. Cancer's sweet tooth for serine. Breast Cancer Research : Bcr. 13: 317. PMID 22189202 DOI: 10.1186/bcr2932  0.68
2010 Kaneko K, Ueki K, Takahashi N, Hashimoto S, Okamoto M, Awazawa M, Okazaki Y, Ohsugi M, Inabe K, Umehara T, Yoshida M, Kakei M, Kitamura T, Luo J, Kulkarni RN, et al. Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms. Cell Metabolism. 12: 619-32. PMID 21109194 DOI: 10.1016/j.cmet.2010.11.005  0.68
2010 Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Alemán JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC, Kahn CR. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Research. 70: 5305-15. PMID 20530665 DOI: 10.1158/0008-5472.CAN-09-3399  0.68
2009 Hill JW, Xu Y, Preitner F, Fukuda M, Cho YR, Luo J, Balthasar N, Coppari R, Cantley LC, Kahn BB, Zhao JJ, Elmquist JK. Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis. Endocrinology. 150: 4874-82. PMID 19819947 DOI: 10.1210/en.2009-0454  0.68
2009 Acosta-Martínez M, Luo J, Elias C, Wolfe A, Levine JE. Male-biased effects of gonadotropin-releasing hormone neuron-specific deletion of the phosphoinositide 3-kinase regulatory subunit p85alpha on the reproductive axis. Endocrinology. 150: 4203-12. PMID 19541766 DOI: 10.1210/en.2008-1753  0.68
2009 Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene Cell. 137: 835-848. PMID 19490893 DOI: 10.1016/j.cell.2009.05.006  0.68
2009 Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 136: 823-37. PMID 19269363 DOI: 10.1016/j.cell.2009.02.024  0.68
2008 Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, Frangioni JV, Cantley LC. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 105: 9739-44. PMID 18621722 DOI: 10.1073/pnas.0804123105  0.68
2008 Luo J, Elledge SJ. Cancer: Deconstructing oncogenesis Nature. 453: 995-996. PMID 18563141 DOI: 10.1038/453995a  0.68
2008 Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, Cowley MA, Cantley LC, Lowell BB, Elmquist JK. Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. The Journal of Clinical Investigation. 118: 1796-805. PMID 18382766 DOI: 10.1172/JCI32964  0.68
2008 Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, et al. Cancer proliferation gene discovery through functional genomics Science. 319: 620-624. PMID 18239126 DOI: 10.1126/science.1149200  0.68
2007 Solimini NL, Luo J, Elledge SJ. Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells Cell. 130: 986-988. PMID 17889643 DOI: 10.1016/j.cell.2007.09.007  0.68
2007 Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage Science. 316: 1160-1166. PMID 17525332 DOI: 10.1126/science.1140321  0.68
2007 Chang JD, Sukhova GK, Libby P, Schvartz E, Lichtenstein AH, Field SJ, Kennedy C, Madhavarapu S, Luo J, Wu D, Cantley LC. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America. 104: 8077-82. PMID 17483449 DOI: 10.1073/pnas.0702663104  0.68
2007 Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 129: 289-301. PMID 17412408 DOI: 10.1016/j.cell.2007.03.009  0.68
2007 Taniguchi CM, Aleman JO, Ueki K, Luo J, Asano T, Kaneto H, Stephanopoulos G, Cantley LC, Kahn CR. The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance. Molecular and Cellular Biology. 27: 2830-40. PMID 17283057 DOI: 10.1128/MCB.00079-07  0.68
2007 Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood. 109: 2894-902. PMID 17164340 DOI: 10.1182/blood-2006-07-038620  0.68
2006 Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proceedings of the National Academy of Sciences of the United States of America. 103: 16882-7. PMID 17071741 DOI: 10.1073/pnas.0607984103  0.68
2006 Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K, Cantley LC, Kahn CR. Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proceedings of the National Academy of Sciences of the United States of America. 103: 12093-7. PMID 16880400 DOI: 10.1073/pnas.0604628103  0.68
2006 Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews. Genetics. 7: 606-19. PMID 16847462 DOI: 10.1038/nrg1879  0.68
2006 Luo J, Sobkiw CL, Hirshman MF, Logsdon MN, Li TQ, Goodyear LJ, Cantley LC. Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metabolism. 3: 355-66. PMID 16679293 DOI: 10.1016/j.cmet.2006.04.003  0.68
2006 Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metabolism. 3: 343-53. PMID 16679292 DOI: 10.1016/j.cmet.2006.04.005  0.68
2006 Yuan H, Luo J, Weissleder R, Cantley L, Josephson L. Wortmannin-C20 conjugates generate wortmannin. Journal of Medicinal Chemistry. 49: 740-7. PMID 16420059 DOI: 10.1021/jm050699p  0.68
2005 Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Research. 65: 10992-1000. PMID 16322248 DOI: 10.1158/0008-5472.CAN-05-2612  0.68
2005 Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, Logsdon MN, Horner JW, DePinho RA, Izumo S, Cantley LC. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Molecular and Cellular Biology. 25: 9491-502. PMID 16227599 DOI: 10.1128/MCB.25.21.9491-9502.2005  0.68
2005 Luo J, Cantley LC. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle (Georgetown, Tex.). 4: 1309-12. PMID 16131837  0.68
2005 Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. The Journal of Cell Biology. 170: 455-64. PMID 16043515 DOI: 10.1083/jcb.200503088  0.68
2005 Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America. 102: 10238-43. PMID 16006513 DOI: 10.1073/pnas.0504378102  0.68
2005 Yuan H, Luo J, Field S, Weissleder R, Cantley L, Josephson L. Synthesis and activity of C11-modified wortmannin probes for PI3 kinase. Bioconjugate Chemistry. 16: 669-75. PMID 15898736 DOI: 10.1021/bc049714f  0.68
2003 Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 4: 257-62. PMID 14585353 DOI: 10.1016/S1535-6108(03)00248-4  0.68
Show low-probability matches.